Project description DEENESFRITPL New drug treatment for alcoholism Alcoholism, or alcohol use disorder (AUD) is a major concern across the EU and worldwide. Treatment usually involves a difficult detoxification process requiring physical and mental support to help the patient give up alcohol. Current drug therapies are not optimal and may result in serious side effects. The EU-funded StopAddict project is preparing to reverse this trend. The project will bring to market a new drug called KT-110. Developed by the French company Kinnov-Therapeutics, this new first-in-class drug will allow patients to control their alcohol consumption. The efficacy of KT-110, following 20 years of research and pre-clinical development, is related to its action on a newly discovered pathway that is highly implicated in alcohol addiction. Show the project objective Hide the project objective Objective Alcohol use disorders (AUD) is a disease characterised by uncontrolled alcohol consumption. 283 million persons worldwide suffer from alcohol mise use which cause more than 3 million dead and 132.6 million disability-adjusted life years. Alcoholism has also huge damaging effects on families, communities and the overall society. Current drug therapies against AUD are unsuccessful due to poor efficacy and strong side effects. That situation leads to low patient recovery and only 10% of AUD people seeking for treatment. In this context, Kinnov-Therapeutics has developed a new revolutionary first-in-class drug allowing patients to control their alcohol consumption. KT-110 drug will highly impact the European burden of AUD by decreasing alcohol consumption on AUD patients by 70% leading to triple the number of AUD people seeking for treatments and save more than 5 million lives per year and several billion of social cost expenses. The efficacy of KT-110 is related to its action on a newly discovered pathway highly implicated in alcohol addiction. This major understanding of AUD addiction mechanism was granted the European college of neuropsychopharmacology Neuropsychopharmacology Award in 2009. After 20 years of intensive research and pre-clinical development, KT-110 has been accepted by the french regulatory agency for its first-in man phase II clinical trial by the end of 2018. This will be the main achievement of SMEi2 project. Moreover, all necessary actions for successful commercialisation to pharma companies (licensing deals) as well as continuous and updated IP and FTO issues are planned to be implemented during the SMEi2. Through StopAddict project KT-110 will become the next leader of AUD treatments by generating €117m of cumulative revenues between 2025-2027. Our project will also allow to create more than 400 direct and indirect European jobs. Fields of science natural scienceschemical sciencesorganic chemistryalcohols Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-2 Funding Scheme SME - SME instrument Coordinator KINNOV THERAPEUTICS Net EU contribution € 2 402 680,00 Address 3 ALLEE DU TITANE 45100 Orleans France See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Centre — Val de Loire Centre — Val de Loire Loiret Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 3 859 659,00
